Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

49 results about "Heparin coating" patented technology

Heparin coatings work by preventing platelet adhesion and activation, events that must be minimized to maintain blood compatibility. Heparin is a highly charged molecule that interferes with the blood-clotting mechanisms by catalyzing the inactivation of enzymes—such as thrombin and Factor X a—in the fibrin cascade.

In-vitro non-implantable maglev heart chamber assisting centrifugal blood pump

The invention belongs to the field of medical apparatuses, and relates to an artificial heart assisting device for treating heart failure caused by acute cardiogenic shock, in particular to an in-vitro non-implantable maglev heart chamber assisting centrifugal blood pump. The in-vitro non-implantable maglev heart chamber assisting centrifugal blood pump adopts a non-bearing magnetic fluid levitation technology to substitute mechanical bearing driving of the conventional centrifugal blood pump, an impeller rotor is suspended in a magnetic field without any mechanical contact, and the position and the speed of the impeller rotor are precisely regulated by a digital signal processor system, so that damage to blood cells and visible components (platelets, blood coagulation factors and the like) of blood is reduced to the most extent; meanwhile, by a heparin coating technology applicable to the inner wall of the blood pump and the surface of the impeller rotor, coagulation and thrombosis as well as use of an anticoagulant medicine in the assisting process are further reduced, so that complications of hemorrhage of a patient during a surgery are reduced. The in-vitro non-implantable maglev heart chamber assisting centrifugal blood pump has the characteristics of being simple in structure, reliable in operation, convenient to maintain, stepless in speed regulation and the like, can be used for treating the heart failure caused by acute cardiogenic shock triggered by a variety of reasons, and in combination with an oxygenator, can also be used for assisting circulation and blood oxygenation during extracorporeal membrane oxygenation (ECMO) treatment.
Owner:ZHENGREN BEIJING MEDICAL INSTR CO LTD

Preparation method and application of oxidized low-molecular-weight heparin-antithrombin compounds

The invention discloses a method for preparing oxidized low-molecular-weight heparin-antithrombin compounds and applying the oxidized low-molecular-weight heparin-antithrombin compounds to coating layer used for improving extracorporeal circulation pipeline blood and biocompatibility. The method comprises the following steps: firstly, oxidizing low-molecular-weight heparin through sodium periodate; then, carrying out nonenzymatic glycosylation reaction with antithrombin; obtaining the purified oxidized low-molecular-weight heparin-antithrombin compounds through centrifugal ultrafiltration and diethylaminoethyl-agarose high-flowing-speed anion exchange chromatography; and then, using the polymine-glutaric dialdehyde combining technology for immobilizing the low-molecular-weight heparin-antithrombin compounds on the surface of the extracorporeal circulation pipeline. The extracorporeal circulation pipeline of the oxidized low-molecular-weight heparin-antithrombin compound coating layer prepared by the invention has better coating layer stability, anticoagulation performance and biocompatibility than the extracorporeal circulation pipeline of the heparin coating layer and low-molecular-weight heparin coating layer, the inflammatory mediator generation and release and the blood coagulation system activation caused by the contact of blood with the surface of the extracorporeal circulation pipeline can be lightened.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

Manufacturing method of temperature-sensitive hydrogel compound coating intravascular stent

The invention relates to a manufacturing method of a temperature-sensitive hydrogel compound coating intravascular stent. The method comprises the steps of surface alkalization treatment of a bare metal intravascular stent, medicament coating, hydroxybutyl chitosan coating, heparin coating and the like, so that an intelligent change effect from dissolving to gelling of a hydroxybutyl chitosan coating material is achieved. The manufactured temperature-sensitive hydrogel compound coating intravascular stent has high biocompatibility and biodegradability, is resistant to erosion, and has a more proper mechanical strength to endangium. A formed porous aqueous structure can realize controlled release of coated clinical treatment medicaments such as rapamycin, paclitaxel and the like, inhibit excessive proliferation of smooth muscle cells, accelerate endothelialization and prevent thrombosis and restenosis. A technology applied in the method is the combination and breakthrough of a drug loading technology and a temperature-sensitive hydrogel technology on the aspect of the research of stent surface coating materials, and the medical problem of restenosis after the placement of the stent is solved; the stent can become an ideal cardiovascular functional interface coating material, and has important theoretical significance and application value.
Owner:QINGDAO UNIV

Modified polymeric membrane material and preparation method thereof

The invention relates to a modified polymeric membrane material and a preparation method thereof. The modified polymeric membrane material is mainly characterized in that the surface of the polymeric membrane material is grafted with two coatings having a substance with anticoagulant action, namely a phosphorylcholine zwitterion coating and a heparin coating. The preparation method of the coating comprises the following steps: step 1, grafting the surface of the polymeric membrane material with phosphorylcholine and acrylamide copolymer; step 2, putting the treated polymeric membrane material into a cleaning solution for cleaning, soaking and drying; and step 3, reacting residual amino groups grafted on the polymeric membrane material dried in step 2 with a EDC and NHS-activated heparin solution obtain the modified polymeric membrane material with the surface compounded and grafted with the phosphorylcholine zwitterion coating and the heparin coating. The preparation method can prepare the modified polymeric membrane material which is good in mechanical property, good in hydrophilicity and long-acting in anticoagulation. The prepared heparin coating is uniform, the heparin grafting amount is high and can reach 6.3 [mu]g/cm<2>, and the heparin coating has a good market prospect.
Owner:NINGBO JENSCARE BIOTECHNOLOGY CO LTD

Membrane-type oxygen exchange device

The invention relates to a membrane-type oxygen exchange device. The membrane-type oxygen exchange device is used for removing carbon dioxide in blood and enriching oxygen in the blood, and comprises a hexahedron housing and a core mounted in the housing, wherein the bottom and the corresponding top of the hexahedron housing are provided with a venous blood inlet and an arterial blood outlet respectively, and a set of opposite sides of the hexahedron housing are provided with an oxygen inlet and a carbon dioxide outlet respectively; the core is a hollow semipermeable membrane fiber bundle formed by a plurality of semipermeable membranes, and one end of each semipermeable membrane is communicated with the oxygen inlet while the other end of each semipermeable membrane is communicated with the carbon dioxide outlet; the outer surface of each semipermeable membrane is coated with a heparin coating, and the blood enters the housing through the venous blood inlet, and undergoes blood oxygen exchange with oxygen which enters the semipermeable membranes from the oxygen inlet; produced carbon dioxide is discharged from the carbon dioxide outlet, and the blood which completes the blood oxygen exchange is discharged from the arterial blood outlet. According to the membrane-type oxygen exchange device, the formation of thrombus in the blood can be effectively inhibited, and the gas exchange efficiency is improved.
Owner:裴嘉阳

Minimally invasive upper and lower vena cava and coronary sinus drainage catheter

The invention discloses a minimally invasive upper and lower vena cava and coronary sinus drainage catheter, which comprises a vein drainage pipeline with a heparin coating and a coronary sinus blocking balloon; side holes of two areas are formed in the vein drainage pipeline; furthermore, the side holes of the two areas are located in the mirror surface position of an upper cavity and the mirror surface position of a lower cavity respectively to achieve the effect of fully draining blood; the vein drainage pipeline located in the upper vena cava position and the vein drainage pipeline located in the lower vena cava position are sleeved with an upper cavity blocking balloon and a lower cavity blocking balloon respectively; the vein drainage pipeline located in the middle of an upper vena cava blocking balloon and a lower vena cava blocking balloon is connected with a side pipe; the side pipe is sleeved with the coronary sinus blocking balloon; the upper cavity blocking balloon, the lower cavity blocking balloon and the coronary sinus blocking balloon are all connected with one-way valves to achieve inflation of injected gas; and the minimally invasive upper and lower vena cava and coronary sinus drainage catheter has the following technical features that: the number of intubations and the time of suture separation can be reduced; additional exploration and hemostasis are not needed; the operation space and efficiency are effectively increased; and the clear view can be ensured.
Owner:SHANGHAI CHANGZHENG HOSPITAL

Composite lipid nanocapsule composition and preparation method and application thereof

The invention discloses a composite lipid nanocapsule composition and a preparation method and application thereof, and belongs to the technical field of medicines. The composite lipid nanocapsule composition is formed by combining a lipid core with negative charges on the surface, a first capsule wall layer with positive charges and a second capsule wall layer with negative charges through electrostatic adsorption between positive and negative charge groups, and can be used for intravenous injection, wherein the lipid core is a depot loaded with an anti-tumor drug, chitosan has the effects ofpromoting transmembrane transport, controlling drug release and the like, and low-molecular heparin coating the outer side of the nanocapsule can react with heparinase so that the nanocapsule is enriched and degraded at a malignant tumor part, and a tumor targeting function is realized. Besides, a carrier material used by the composition is high in biological safety, good in tumor targeting property, high in drug encapsulation efficiency, good in stability, controllable in release and simple in preparation method, and has a wide application prospect when being used for targeted delivery of antitumor drugs.
Owner:INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products